PRRT2 and hepatocellular carcinoma: Whilst many of the treated TPCS appeared viable at day 8, the first-line HCC therapy sorafenib unsurprisingly caused a drastic reduction in metabolic activity and ATP production comparable to two additional drugs in the screen, the antibiotic salinomycin and the PKC inhibitor rottlerin (Figures 6C, D).